Key Slides on Hepatitis B Pretreatment Evaluation

Review AASLD guideline recommendations informing HBV pretreatment evaluation, including serology, HBV DNA, and fibrosis assessments to determine treatment candidacy.
Paul Y. Kwo, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.49 MB
Released: February 16, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from:
Gilead Sciences, Inc.

Related Content

Download this PDF guide outlining key information on HCC risk assessment, screening, and surveillance in the setting of Hepatitis B infection

Robert S. Brown, Jr., MD, MPH Released: February 22, 2021

Expert CCO commentary on how to incorporate noninvasive methods to assess fibrosis into management of patients with HBV infection

Paul Y. Kwo, MD Released: February 18, 2021

Watch this brief presentation by Dr. Paul Kwo on interpreting serology, HBV DNA, and fibrosis assessments to determine HBV treatment candidacy.

Paul Y. Kwo, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 16, 2021 Expired: February 15, 2022

From Clinical Care Options (CCO), download a PDF featuring expert discussion on using immunotherapy for patients with advanced HCC

Lipika Goyal, MD Amit G. Singal, MD, MS Released: January 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue